COVERSYL PLUS

This brand name is authorized in Australia, Brazil, Canada, Ireland, Malta, Nigeria, Netherlands, Singapore, Turkey, South Africa

Active ingredients

The drug COVERSYL PLUS contains a combination of these active pharmaceutical ingredients (APIs):

1 Perindopril
UNII 1964X464OJ - PERINDOPRIL ERBUMINE

Perindopril is an inhibitor of the enzyme that converts angiotensin I into angiotensin II (Angiotensin Converting Enzyme ACE). The converting enzyme, or kinase, is an exopeptidase that allows conversion of angiotensin I into the vasoconstrictor angiotensin II as well as causing the degradation of the vasodilator bradykinin into an inactive heptapeptide. Inhibition of ACE results in a reduction of angiotensin II in the plasma, which leads to increased plasma renin activity (by inhibition of the negative feedback of renin release) and reduced secretion of aldosterone. Since ACE inactivates bradykinin, inhibition of ACE also results in an increased activity of circulating and local kallikrein-kinin systems (and thus also activation of the prostaglandin system).

Read about Perindopril
2 Indapamide
UNII F089I0511L - INDAPAMIDE

Indapamide is a sulfonamide derivative with an indole ring, pharmacologically related to thiazide diuretics, which acts by inhibiting the reabsorption of sodium in the cortical dilution segment. It increases the urinary excretion of sodium and chlorides and, to a lesser extent, the excretion of potassium and magnesium, thereby increasing urine output and having an antihypertensive action.

Read about Indapamide

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
COVERSYL PLUS Tablet Health Products Regulatory Authority (ZA) MPI, Generic

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C09BA04 Perindopril and diuretics C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09B ACE inhibitors, combinations → C09BA ACE inhibitors and diuretics
Discover more medicines within C09BA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 2190G, 2845R
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 531301901114310, 531301902110319
Country: CA Health Products and Food Branch Identifier(s): 02246568, 02246569, 02321653
Country: IE Health Products Regulatory Authority Identifier(s): 19415, 19505, 19512
Country: MT Medicines Authority Identifier(s): MA066/00305, MA066/01802
Country: NG Registered Drug Product Database Identifier(s): B4-4159
Country: NL Z-Index G-Standaard, PRK Identifier(s): 85146, 90093
Country: SG Health Sciences Authority Identifier(s): 10825P, 13633P, 13634P, 13823P
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699552010562, 8699552090472, 8699552090489
Country: ZA Health Products Regulatory Authority Identifier(s): 33/7.1.3/0363, 42/7.1.3/0167

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.